Category: Apollo Endosurgery
Apollo Endosurgery closes the books on its acquisition of Allergan's obesity intervention business, including the Lap-Band and Orbera technologies, in a deal worth up to $110 million.
Medtech company Allergan (NYSE:AGN) officially dumped its obesity interventions business, consummating with Apollo Endosurgery a deal worth up to $110 million.
Apollo Endosurgery inks a deal with Allergan to acquire its obesity intervention business for up to $110 million.
Almost exactly 1 year after saying it would seek a buyer for its Lap-Band obesity device, Allergan (NYSE:AGN) said today that Apollo Endosurgery agreed to spend up to $110 million on Allergan's obesity intervention business, which includes the Orbera intra-gastric balloon.
The $372 million buyout of Navilyst medical is expected to add 8 cents per share to AngioDynamics' books during fiscal 2013; also, Orasi Medical closes up shop; Becton, Dickinson reveals medical device tax impact; Abiomed hits 52-week high; analysts' ups and downs; and the MassDevice.com Funding Roundup.
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.